MedTrace Logo

Predictive Role of KLK10 and Other Neuroinflammatory Molecules on Clinical Outcomes of AIS

NCT06549972 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 273

Last updated 2025-07-29

No results posted yet for this study

Summary

This study aims to investigate the dynamic changes and differential expression characteristics of neuroinflammatory molecules such as kallikrein-related peptidase 10 (KLK10), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), and glial fibrillary acidic protein (GFAP) in the plasma of patients with first-ever anterior circulation acute ischemic stroke (AIS). It will analyze the correlation between these molecules and the severity of neurological deficits, infarct volume, brain edema, hemorrhagic transformation, progressive stroke, and clinical outcomes at three months. The goal is to assess the predictive value of these molecules for AIS prognosis, guiding early treatment and new molecular targets for prevention and treatment.

Conditions

Interventions

OTHER

Acute Ischemic Stroke

first-ever anterior circulation AIS (Acute Ischemic Stroke)

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Longxuan Li, Doctor · Ruijin Hospital Affiliated to Shanghai Jiao Tong University School

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-12
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06549972 on ClinicalTrials.gov